SCHEMBL254259

SCHEMBL254259

C#CC[C@H](N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1429407 1.00
SCHEMBL40887 1.00
Hydrochloric Acid SCHEMBL22778013 0.97
Hydrochloric Acid SCHEMBL22778011 0.97
Hydrochloric Acid SCHEMBL29956197 0.97
SCHEMBL2650618 0.81 GRIK1 (0.47)
SCHEMBL7700595 0.80 GRIK1 (1.00)
SCHEMBL27773703 0.80 GRIK1 (0.66)
SCHEMBL15310777 0.80 GRIK1 (1.00)
SCHEMBL7785618 0.80 GRIK1 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122074077-A Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte stimulating hormone analogs for imaging or therapy 省卫生服务机构 2026-05-22 CN claimed
EP-4211146-B1 SYNTHETIC CYCLIC PEPTIDE MIMETICS UNIV BAR ILAN (IL) 2026-05-20 EP claimed
CN-122051971-A Safety control method and system for new energy power system 南通职业大学 2026-05-15 CN claimed
US-12616760-B2 Synthetic cyclic peptide mimetics BAR ILAN UNIVERSITY (IL) 2026-05-05 US claimed
EP-4720087-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 EP claimed
CN-121570433-A Glutamine metabolism regulation nano drug delivery system for enhancing pancreatic cancer targeting and penetration, and preparation method and application thereof 复旦大学 2026-02-27 CN claimed
US-12486304-B2 Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof C-BIOMEX CO., LTD. (KR) 2025-12-02 US claimed
EP-4652180-A2 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Janssen Pharmaceutica NV (BE) 2025-11-26 EP claimed
EP-4652179-A1 LIPIDATED PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Janssen Pharmaceutica NV (BE) 2025-11-26 EP claimed
EP-4652181-A1 POLYCYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Janssen Pharmaceutica NV (BE) 2025-11-26 EP claimed
WO-2015191951-A2 MODULATION OF COMPLEMENT ACTIVITY RA PHARMACEUTICALS, INC. (US) 2015-12-17 WO claimed
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. 2015-10-01 US claimed
EP-2877175-A2 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS Sova Pharmaceuticals, Inc. (US) 2015-06-03 EP claimed
US-20140056812-A1 Imaging Beta Cell Mass THE GENERAL HOSPITAL CORPORATION (US) 2014-02-27 US claimed
WO-2014018571-A2 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. (US) 2014-01-30 WO claimed
US-8466108-B2 TFPI inhibitors and methods of use BAXTER INTERNATIONAL INC. (US) 2013-06-18 US claimed
WO-2012121746-A2 IMAGING BETA CELL MASS THE GENERAL HOSPITAL CORPORATION (US) 2012-09-13 WO claimed
US-20110263815-A1 TRIAZOLE MACROCYCLE SYSTEMS AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) 2011-10-27 US claimed
EP-2379096-A2 TFPI INHIBITORS AND METHODS OF USE Baxter International Inc. (US) 2011-10-26 EP claimed
WO-2010071894-A2 TFPI INHIBITORS AND METHODS OF USE BAXTER INTERNATIONAL INC. (US) 2010-06-24 WO claimed